Strengthening its oncology pipeline, Pfizer signed a deal with Swedish biotech, BioInvent, for the research, development and commercialisation of the latter’s novel tumour-associated myeloid cells (TAM) targeted antibodies. The agreement includes an upfront payment to BioInvent of approximately US$10 M and, up to US$500 M in milestones dependent upon the successful commercialisation of five candidates along with sales-based, double-digit royalties and a US$6 M investment into new shares of the company by Pfizer. BioInvent’s proprietary FIRST™ platform will be leveraged for the discovery of candidates and their targets.